Markets

Insider Trading

Hedge Funds

Retirement

Opinion

15 Most Advanced Countries in Biomedical Engineering

Page 1 of 5

In this article, we will look at the 15 most advanced countries in biomedical engineering. You can also see the 10 Best Biotech Penny Stocks to Buy Now.

The biotechnology global market size was estimated at $1.38 trillion in 2023 and is expected to reach around $4.25 trillion by 2033 while growing at a CAGR of 11.8%. North America led the market with a 37.79% revenue share in 2023 owing to the strong R&D initiatives and high healthcare expenses. Meanwhile, the Asia-Pacific region is anticipated to grow at the fastest rate, with a CAGR of over 12.7% during the forecast period, due to improved healthcare infrastructure and supportive government regulations.

The bio-pharmacy segment, which captured 41.73% of the revenue share in 2023, is a major driver due to the increasing demand for medicines and drugs. Additionally, tissue engineering and regeneration technologies, which dominated the market by technology with a 19.26% share, are expanding tremendously in different healthcare domains.

In 2023 alone, the FDA approved 53 new drugs, with over 60% originating from biotech firms. The adoption of CRISPR technology for gene editing and the development of monoclonal antibodies for targeted therapies have only confirmed the sector’s potential. Additionally, the integration of artificial intelligence (AI) in biotechnology is speeding up research and development processes in the industry.

However, despite these developments, the biotechnology industry is facing some challenges. According to the EY Biotechnology Report 2024, there is a mixed landscape where only companies with strong clinical data or nearly marketed assets can attract high investments. In 2023, venture capital funding for biotech startups dropped by 28%.

Before getting into biomedical engineering as a profession and its developments around the world, let’s look at the key players in the biotech market.

Amgen Inc (NASDAQ:AMGN) reported nearly $26 billion in revenue in 2022 which is attributed largely to its diverse portfolio of treatments. Amgen Inc (NASDAQ:AMGN)’s flagship products, including the osteoporosis drug Prolia and the cholesterol-lowering Repatha, have collectively brought in billions.

One of Amgen Inc (NASDAQ:AMGN)’s major victories was the development and marketing of sotorasib, branded as Lumakras, which targets the KRAS G12C mutation in lung cancer. Since its launch in 2021, Lumakras has provided major benefits to patients like Don Crosslin, despite its high toxicity and $20,000 monthly cost. In 2023, Lumakras generated nearly $200 million in US sales.

On the other hand, Moderna Inc (NASDAQ:MRNA) has received $176 million in federal funding to develop mRNA vaccines against the H5N1 bird flu virus. This funding will support the late-stage development of an mRNA-based vaccine designed to fight the highly contagious H5N1 influenza virus, which has been causing alarm as it spreads among animals and occasionally infects humans.

Since 2023, Moderna Inc (NASDAQ:MRNA) has been conducting early-stage clinical trials for mRNA pandemic flu vaccines to target the H5 and H7 strains known for their potential to become highly virulent. Results from these trials are expected in 2024 and will guide the late-stage development of the vaccine. The newly formed Rapid Response Partnership Vehicle (RRPV) is funding Moderna Inc (NASDAQ:MRNA)’s project along with other initiatives to address emerging infectious diseases and biological threats.

Apart from the developed countries, some developing economies like India have been at the forefront of research and innovation in biomedical engineering. For example, according to the Scimago Institution Ranking, there are 120 top biomedical engineering research institutions in India. However, since salaries in India are relatively far less than the ones offered in developed countries, India didn’t make it to our list of the most advanced countries in biomedical engineering.

When looking for biomedical engineering jobs abroad, professionals can find roles in the research, development, and implementation of medical devices, prosthetics, and diagnostic equipment. Countries with strong healthcare sectors, such as the USA, Germany, and Singapore, often have a high demand for biomedical engineers.

Also see 15 Most Profitable Biotechnology Companies in the World and 20 Biggest Publicly Traded Biotech Companies.

A biomedical engineer studying data from an ERK1/2 inhibitor experiment.

Our Methodology

To identify the most advanced countries in biomedical engineering, we utilized the Scimago Institution Rankings with a focus on research and innovation output and also analyzed the average salaries of biomedical engineers globally. We selected the top 25 countries with the highest number of leading institutions in biomedical engineering and the top 30 countries with the highest average salaries for biomedical engineers. Each country was then ranked within these two categories, with a rank of 1 representing the highest number of top institutions and the highest average salary, respectively.

The rationale for using the metric of high average salaries was that it gave us countries with thriving biomedical-engineering markets, which indirectly shows these countries are not only advancing technologically in the field, they’re also likely attracting talent from across the world.

Next, we calculated the average rank for each country by combining its rank in research and innovation with its rank in average salary. This provided us with an average composite score. In cases where countries had identical average ranks, the country with the higher rank in research and innovation was ranked higher. The list is presented in ascending order (from low to high rank).

At Insider Monkey we are obsessed with the stocks that hedge funds pile into. The reason is simple: our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds. Our quarterly newsletter’s strategy selects 14 small-cap and large-cap stocks every quarter and has returned 275% since May 2014, beating its benchmark by 150 percentage points (see more details here).

15. Singapore

Research and Innovation Rank: 15

Average Salary Rank: 13

Overall Rank: 14

According to the Scimago Institution Ranking, there are 18 top biomedical engineering institutions in Singapore. The average salary of a biomedical engineer in the country is $78,773.

14. Spain

Research and Innovation Rank: 9

Average Salary Rank: 19

Overall Rank: 14

The University of Barcelona is one of the best universities to study biomedical engineering in Spain. The average salary of a biomedical engineer in Spain is $63,558. There are 65 innovative biomedical engineering institutions in the country, according to the Scimago rankings.

13. Japan

Research and Innovation Rank: 7

Average Salary Rank: 20

Overall Rank:  13.5

Japan is highly advanced in biomedical engineering, particularly in radiology and imaging technologies. They pioneered X-ray technology in 1896 and have continuously innovated, such as developing the first upright 320-channel CT machine in 2017. Nature notes that Japan leads in AI integration for diagnostic imaging, supported by a national database with over 500 million images. They are global leaders in particle beam therapy for cancer treatment and have made important contributions to neuroscience through magnetic resonance studies.

12. Netherlands

Research and Innovation Rank: 14

Average Salary Rank: 12

Overall Rank: 13

With an average salary of $79,485, the Netherlands is one of the countries that pay biomedical engineers the most. The country is home to leading institutions like the University of Twente and Delft University of Technology, which excel in areas such as medical robotics, imaging, and tissue engineering.

11. Italy

Research and Innovation Rank: 8

Average Salary Rank: 17

Overall Rank: 12.5

The average salary of a biomedical engineer in Italy is $63,923. The University of Rome III and the Polytechnic University of Milan are two major institutions that offer the best degree courses in biomedical engineering in Italy.

10. China

Research and Innovation Rank: 1

Average Salary Rank: 24

Overall Rank: 12.5

China is the leader in innovation and research in the domain of biomedical engineering as there are around 505 top institutions in Scimago’s list of highest-ranked biomedical engineering institutions. The average salary of a biomedical engineer in China is $44,560.

9. Denmark

Research and Innovation Rank: 20

Average Salary Rank: 4

Overall Rank: 12

Denmark is a global leader in biomedical engineering which is particularly advancing in quantum sensing technology for early disease detection. With a grant of DKK 150 million (around $29 million) from the Novo Nordisk Foundation, the Copenhagen Center for Biomedical Quantum Sensing has been established. This center is a collaboration between the University of Copenhagen, the Technical University of Denmark, and the University of Texas at Austin and has a focus on developing highly sensitive sensors to enable the detection of faint biological signals from the nerves, heart, or brain.  Given the strong work ethic in Denmark along with an emphasis on work-life balance, Denmark is one of the best countries for a biomedical engineering job.

8. United Kingdom

Research and Innovation Rank: 6

Average Salary Rank: 18 

Overall Rank: 12

Owing to the high salaries in London, it is also one of the best cities for biomedical engineers. According to the Scimago Institution Ranking, there are 80 top-ranking biomedical engineering institutions in the UK. The average salary of a biomedical engineer in the UK is $63,848.

7. Belgium 

Research and Innovation Rank: 17

Average Salary Rank: 6

Overall Rank: 11.5

Belgium is a leader in biomedical engineering with an incredible biotech sector with over 300 companies. It is Europe’s second-largest biotech hub which is famous for developments in pharmaceuticals, diagnostics, and medical technology.

6. France

Research and Innovation Rank: 5

Average Salary Rank: 16

Overall Rank: 10.5

France is the hub of biomedical engineering jobs in Europe. We say this because, in 2021, President Macron revealed a €7.5 billion ($8.09 billion) plan to position France as a global leader in healthcare innovation by 2030. From 2020 to 2022, health-tech firms in France increased from 2,050 to 2,640. Importantly, the proportion of companies with international subsidiaries increased to 25%, and 56% of medical-tech firms now have market-ready products. Paris, accounting for 44% of France’s research output in 2021, remains a central hub.

5. Canada

Research and Innovation Rank: 10

Average Salary Rank: 9

Overall Rank: 9.5

In Canada, biomedical engineers typically earn an average salary of $84,177 per year. This occupation generally requires a university degree, whether a bachelor’s, master’s, or doctorate. Canada is one of the countries with a high demand for biomedical engineers.

Page 1 of 5

AI, Tariffs, Nuclear Power: One Undervalued Stock Connects ALL the Dots (Before It Explodes!)

Artificial intelligence is the greatest investment opportunity of our lifetime. The time to invest in groundbreaking AI is now, and this stock is a steal!

AI is eating the world—and the machines behind it are ravenous.

Each ChatGPT query, each model update, each robotic breakthrough consumes massive amounts of energy. In fact, AI is already pushing global power grids to the brink.

Wall Street is pouring hundreds of billions into artificial intelligence—training smarter chatbots, automating industries, and building the digital future. But there’s one urgent question few are asking:

Where will all of that energy come from?

AI is the most electricity-hungry technology ever invented. Each data center powering large language models like ChatGPT consumes as much energy as a small city. And it’s about to get worse.

Even Sam Altman, the founder of OpenAI, issued a stark warning:

“The future of AI depends on an energy breakthrough.”

Elon Musk was even more blunt:

“AI will run out of electricity by next year.”

As the world chases faster, smarter machines, a hidden crisis is emerging behind the scenes. Power grids are strained. Electricity prices are rising. Utilities are scrambling to expand capacity.

And that’s where the real opportunity lies…

One little-known company—almost entirely overlooked by most AI investors—could be the ultimate backdoor play. It’s not a chipmaker. It’s not a cloud platform. But it might be the most important AI stock in the US owns critical energy infrastructure assets positioned to feed the coming AI energy spike.

As demand from AI data centers explodes, this company is gearing up to profit from the most valuable commodity in the digital age: electricity.

The “Toll Booth” Operator of the AI Energy Boom

  • It owns critical nuclear energy infrastructure assets, positioning it at the heart of America’s next-generation power strategy.
  • It’s one of the only global companies capable of executing large-scale, complex EPC (engineering, procurement, and construction) projects across oil, gas, renewable fuels, and industrial infrastructure.
  • It plays a pivotal role in U.S. LNG exportation—a sector about to explode under President Trump’s renewed “America First” energy doctrine.

Trump has made it clear: Europe and U.S. allies must buy American LNG.

And our company sits in the toll booth—collecting fees on every drop exported.

But that’s not all…

As Trump’s proposed tariffs push American manufacturers to bring their operations back home, this company will be first in line to rebuild, retrofit, and reengineer those facilities.

AI. Energy. Tariffs. Onshoring. This One Company Ties It All Together.

While the world is distracted by flashy AI tickers, a few smart investors are quietly scooping up shares of the one company powering it all from behind the scenes.

AI needs energy. Energy needs infrastructure.

And infrastructure needs a builder with experience, scale, and execution.

This company has its finger in every pie—and Wall Street is just starting to notice.

Wall Street is noticing this company also because it is quietly riding all of these tailwinds—without the sky-high valuation.

While most energy and utility firms are buried under mountains of debt and coughing up hefty interest payments just to appease bondholders…

This company is completely debt-free.

In fact, it’s sitting on a war chest of cash—equal to nearly one-third of its entire market cap.

It also owns a huge equity stake in another red-hot AI play, giving investors indirect exposure to multiple AI growth engines without paying a premium.

And here’s what the smart money has started whispering…

The Hedge Fund Secret That’s Starting to Leak Out

This stock is so off-the-radar, so absurdly undervalued, that some of the most secretive hedge fund managers in the world have begun pitching it at closed-door investment summits.

They’re sharing it quietly, away from the cameras, to rooms full of ultra-wealthy clients.

Why? Because excluding cash and investments, this company is trading at less than 7 times earnings.

And that’s for a business tied to:

  • The AI infrastructure supercycle
  • The onshoring boom driven by Trump-era tariffs
  • A surge in U.S. LNG exports
  • And a unique footprint in nuclear energy—the future of clean, reliable power

You simply won’t find another AI and energy stock this cheap… with this much upside.

This isn’t a hype stock. It’s not riding on hope.

It’s delivering real cash flows, owns critical infrastructure, and holds stakes in other major growth stories.

This is your chance to get in before the rockets take off!

Disruption is the New Name of the Game: Let’s face it, complacency breeds stagnation.

AI is the ultimate disruptor, and it’s shaking the foundations of traditional industries.

The companies that embrace AI will thrive, while the dinosaurs clinging to outdated methods will be left in the dust.

As an investor, you want to be on the side of the winners, and AI is the winning ticket.

The Talent Pool is Overflowing: The world’s brightest minds are flocking to AI.

From computer scientists to mathematicians, the next generation of innovators is pouring its energy into this field.

This influx of talent guarantees a constant stream of groundbreaking ideas and rapid advancements.

By investing in AI, you’re essentially backing the future.

The future is powered by artificial intelligence, and the time to invest is NOW.

Don’t be a spectator in this technological revolution.

Dive into the AI gold rush and watch your portfolio soar alongside the brightest minds of our generation.

This isn’t just about making money – it’s about being part of the future.

So, buckle up and get ready for the ride of your investment life!

Act Now and Unlock a Potential 100+% Return within 12 to 24 months.

We’re now offering month-to-month subscriptions with no commitments.

For a ridiculously low price of just $9.99 per month, you can unlock our in-depth investment research and exclusive insights – that’s less than a single fast food meal!

Space is Limited! Only 1000 spots are available for this exclusive offer. Don’t let this chance slip away – subscribe to our Premium Readership Newsletter today and unlock the potential for a life-changing investment.

Here’s what to do next:

1. Head over to our website and subscribe to our Premium Readership Newsletter for just $9.99.

2. Enjoy a month of ad-free browsing, exclusive access to our in-depth report on the Trump tariff and nuclear energy company as well as the revolutionary AI-robotics company, and the upcoming issues of our Premium Readership Newsletter.

3. Sit back, relax, and know that you’re backed by our ironclad 30-day money-back guarantee.

Don’t miss out on this incredible opportunity! Subscribe now and take control of your AI investment future!


No worries about auto-renewals! Our 30-Day Money-Back Guarantee applies whether you’re joining us for the first time or renewing your subscription a month later!

A New Dawn is Coming to U.S. Stocks

I work for one of the largest independent financial publishers in the world – representing over 1 million people in 148 countries.

We’re independently funding today’s broadcast to address something on the mind of every investor in America right now…

Should I put my money in Artificial Intelligence?

Here to answer that for us… and give away his No. 1 free AI recommendation… is 50-year Wall Street titan, Marc Chaikin.

Marc’s been a trader, stockbroker, and analyst. He was the head of the options department at a major brokerage firm and is a sought-after expert for CNBC, Fox Business, Barron’s, and Yahoo! Finance…

But what Marc’s most known for is his award-winning stock-rating system. Which determines whether a stock could shoot sky-high in the next three to six months… or come crashing down.

That’s why Marc’s work appears in every Bloomberg and Reuters terminal on the planet…

And is still used by hundreds of banks, hedge funds, and brokerages to track the billions of dollars flowing in and out of stocks each day.

He’s used this system to survive nine bear markets… create three new indices for the Nasdaq… and even predict the brutal bear market of 2022, 90 days in advance.

Click to continue reading…